Tag: Aimmune Therapeutics
Peanut OIT Phase 3 Trial Results Show Therapy Effective for Ages...
Aimmune plans to submit a Biologics License Application for AR101 to the FDA by the end of 2018.
Aimmune to Submit FDA Application for Peanut OIT Candidate by End...
If approved, AR101 could be offered as the first FDA approved OIT therapy for peanut allergy.
Results of Phase III Trial of Aimmune's Peanut OIT Therapy
After one year, 3/4 of patients ages 4-17 who received the therapy were able to consume a minimum of 300mg of peanut. Results for adults were less clear.
Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate
The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Aimmune Begins Patient Enrollment for Phase III Clinical Trial of Peanut...
First of 440 patients enrolled in study of AR101.
Breakthrough Food Allergy Therapies and the Big Business Behind Them
What it means to be a breakthrough therapy, who is developing them, how they work, and the (big) business drivers behind them.
